CA2668320A1 - Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel - Google Patents
Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel Download PDFInfo
- Publication number
- CA2668320A1 CA2668320A1 CA002668320A CA2668320A CA2668320A1 CA 2668320 A1 CA2668320 A1 CA 2668320A1 CA 002668320 A CA002668320 A CA 002668320A CA 2668320 A CA2668320 A CA 2668320A CA 2668320 A1 CA2668320 A1 CA 2668320A1
- Authority
- CA
- Canada
- Prior art keywords
- androstanediol
- alpha
- sexual dysfunction
- ht1a agonist
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CBMYJHIOYJEBSB-KHOSGYARSA-N 5alpha-androstane-3alpha,17beta-diol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-KHOSGYARSA-N 0.000 title claims abstract 12
- 239000003723 serotonin 1A agonist Substances 0.000 title claims abstract 10
- 201000001880 Sexual dysfunction Diseases 0.000 title claims 5
- 231100000872 sexual dysfunction Toxicity 0.000 title claims 5
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract 4
- 206010057671 Female sexual dysfunction Diseases 0.000 claims abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076976A EP1925307A1 (fr) | 2006-11-03 | 2006-11-03 | Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles |
| EP06076976.7 | 2006-11-03 | ||
| PCT/NL2007/050535 WO2008054215A2 (fr) | 2006-11-03 | 2007-11-02 | Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2668320A1 true CA2668320A1 (fr) | 2008-05-08 |
| CA2668320C CA2668320C (fr) | 2014-06-10 |
Family
ID=37846101
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2668320A Expired - Fee Related CA2668320C (fr) | 2006-11-03 | 2007-11-02 | Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel |
| CA2668316A Expired - Fee Related CA2668316C (fr) | 2006-11-03 | 2007-11-02 | Utilisation de testosterone et d'un agoniste de la 5-ht1a dans le traitement d'un dysfonctionnement sexuel |
| CA2668317A Expired - Fee Related CA2668317C (fr) | 2006-11-03 | 2007-11-02 | Utilisation de 3-alpha-androstanediol eventuellement combine a un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2668316A Expired - Fee Related CA2668316C (fr) | 2006-11-03 | 2007-11-02 | Utilisation de testosterone et d'un agoniste de la 5-ht1a dans le traitement d'un dysfonctionnement sexuel |
| CA2668317A Expired - Fee Related CA2668317C (fr) | 2006-11-03 | 2007-11-02 | Utilisation de 3-alpha-androstanediol eventuellement combine a un inhibiteur de la pde5, dans le traitement d'un dysfonctionnement sexuel |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US8653051B2 (fr) |
| EP (5) | EP1925307A1 (fr) |
| JP (8) | JP2010509211A (fr) |
| KR (6) | KR101796887B1 (fr) |
| CN (6) | CN104524580A (fr) |
| AU (3) | AU2007314735B2 (fr) |
| BR (3) | BRPI0718396A2 (fr) |
| CA (3) | CA2668320C (fr) |
| CY (1) | CY1117191T1 (fr) |
| DK (1) | DK2086544T3 (fr) |
| ES (1) | ES2561946T3 (fr) |
| HK (1) | HK1135038A1 (fr) |
| HR (1) | HRP20160108T1 (fr) |
| HU (1) | HUE026752T2 (fr) |
| IL (5) | IL198461A (fr) |
| ME (1) | ME02410B (fr) |
| MX (3) | MX2009004696A (fr) |
| NO (3) | NO343597B1 (fr) |
| NZ (3) | NZ577392A (fr) |
| PH (2) | PH12014501440A1 (fr) |
| PL (1) | PL2086544T3 (fr) |
| PT (1) | PT2086544E (fr) |
| RS (1) | RS54541B1 (fr) |
| RU (4) | RU2463054C2 (fr) |
| SI (1) | SI2086544T1 (fr) |
| UA (4) | UA103592C2 (fr) |
| WO (3) | WO2008054215A2 (fr) |
| ZA (3) | ZA200903836B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1750766E (pt) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
| EP1790343A1 (fr) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme |
| EP1925307A1 (fr) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles |
| EP2266567A1 (fr) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel |
| EP2266568A1 (fr) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel |
| AU2012256501B2 (en) * | 2011-05-13 | 2017-04-06 | Eb Ip Hybritabs B.V. | Drug delivery system |
| PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP5828923B2 (ja) | 2014-01-30 | 2015-12-09 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| WO2015125650A1 (fr) | 2014-02-21 | 2015-08-27 | 国立大学法人高知大学 | Procédé de production de poudre de nickel |
| JP6406613B2 (ja) | 2014-04-15 | 2018-10-17 | 住友金属鉱山株式会社 | 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法 |
| CN103947533B (zh) * | 2014-05-15 | 2015-12-16 | 青岛理工大学 | 生长环境可控的磁化水工厂化豆芽菜生产系统 |
| RU2600845C2 (ru) | 2014-07-04 | 2016-10-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3251436A (en) * | 1965-03-16 | 1966-05-17 | Dayton Steel Foundry Co | Spot-type disk brake |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| DK169601B1 (da) | 1983-10-17 | 1994-12-19 | Duphar Int Res | Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (fr) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | 2-amino-1,2,3,4-tetrahydronaphtalenes a substituants sur le cycle |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| US6174890B1 (en) | 1994-06-02 | 2001-01-16 | Dan Riga | Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof |
| CA2189355A1 (fr) | 1995-03-01 | 1996-09-06 | Yasuo Onoda | Derives d'imidazoquinazoline |
| TR199700930T2 (xx) | 1995-03-14 | 1998-07-21 | Vivus Incorporated | Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit. |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| WO1996036339A2 (fr) | 1995-05-15 | 1996-11-21 | Beth Israel Hospital | Utilisation de composes de dihydrotestosterone pour traiter une dysfonction sexuelle chez l'homme |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| EP0998274B1 (fr) * | 1997-06-23 | 2006-01-18 | Cellegy Pharmaceuticals, Inc | Traitement par administration de microdoses |
| EP1027057A4 (fr) * | 1997-10-28 | 2003-01-02 | Vivus Inc | Traitement du dysfonctionnement sexuel chez la femme |
| US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| US20040014761A1 (en) | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US6246436B1 (en) * | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| JP2002543128A (ja) | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 雌性覚醒障害の処置 |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US7258850B2 (en) | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| EP1207902A2 (fr) | 1999-06-17 | 2002-05-29 | Pharmacia AB | UTILISATION D'HORMONE DE CROISSANCE (hGH) POUR TRAITER LES TROUBLES DE LA FONCTION SEXUELLE |
| RU2180591C2 (ru) * | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| JP2004524267A (ja) * | 2000-08-30 | 2004-08-12 | ユニメッド・ファーマシューティカルズ・インコーポレーテッド | 男性の勃起障害の治療方法、及び性衝動の増強方法 |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| ATE361060T1 (de) | 2000-09-29 | 2007-05-15 | Solvay Pharm Bv | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung |
| US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| JP2004522720A (ja) * | 2000-12-15 | 2004-07-29 | ファイザー・インク | 雄性性的機能障害の処置 |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| KR20040052489A (ko) | 2001-03-06 | 2004-06-23 | 셀러지 파마세우티칼스, 인크 | 비뇨생식기 장애 치료용 화합물 및 그 방법 |
| EE200300469A (et) | 2001-03-28 | 2004-02-16 | Pfizer Inc. | N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul |
| EP1260225A1 (fr) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | Compositions pharmaceutiques pour le traitement hormonal substitutif |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| JP2007516949A (ja) * | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| DE60303854T2 (de) * | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
| WO2005094827A1 (fr) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methodes de traitement d'un dysfonctionnement sexuel |
| BRPI0510074A (pt) | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
| PT1750766E (pt) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
| US20070154533A1 (en) * | 2005-04-13 | 2007-07-05 | Dudley Robert E | Method of increasing testosterone and related steriod concentrations in women |
| WO2006127057A1 (fr) | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Administration vaginale non systématique d'oestrogène et androgène pour le traitement de dysfonctionnement sexuel |
| US8067399B2 (en) * | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (fr) * | 2005-11-08 | 2007-05-18 | L'oréal | Glucuronides androgenes en tant que marqueurs d’activite androgenique |
| EP1790343A1 (fr) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme |
| EP1925307A1 (fr) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles |
| JP5391204B2 (ja) | 2007-11-28 | 2014-01-15 | ウーツェーベー ファルマ ゲーエムベーハー | ロチゴチンの多形体 |
-
2006
- 2006-11-03 EP EP06076976A patent/EP1925307A1/fr not_active Ceased
-
2007
- 2007-02-11 UA UAA200905653A patent/UA103592C2/uk unknown
- 2007-02-11 UA UAA200905652A patent/UA100119C2/uk unknown
- 2007-02-11 ME MEP-2016-33A patent/ME02410B/fr unknown
- 2007-02-11 UA UAA200905654A patent/UA101948C2/uk unknown
- 2007-11-02 CN CN201410844093.6A patent/CN104524580A/zh active Pending
- 2007-11-02 PL PL07834663T patent/PL2086544T3/pl unknown
- 2007-11-02 KR KR1020167028902A patent/KR101796887B1/ko active IP Right Grant
- 2007-11-02 WO PCT/NL2007/050535 patent/WO2008054215A2/fr active Application Filing
- 2007-11-02 ZA ZA200903836A patent/ZA200903836B/xx unknown
- 2007-11-02 RU RU2009120990/15A patent/RU2463054C2/ru not_active IP Right Cessation
- 2007-11-02 CA CA2668320A patent/CA2668320C/fr not_active Expired - Fee Related
- 2007-11-02 KR KR1020157022168A patent/KR20150099620A/ko active Application Filing
- 2007-11-02 MX MX2009004696A patent/MX2009004696A/es not_active Application Discontinuation
- 2007-11-02 ZA ZA200903837A patent/ZA200903837B/xx unknown
- 2007-11-02 DK DK07834663.2T patent/DK2086544T3/en active
- 2007-11-02 SI SI200731745T patent/SI2086544T1/sl unknown
- 2007-11-02 NZ NZ577392A patent/NZ577392A/xx not_active IP Right Cessation
- 2007-11-02 MX MX2009004693A patent/MX2009004693A/es active IP Right Grant
- 2007-11-02 US US12/513,355 patent/US8653051B2/en active Active
- 2007-11-02 NZ NZ577390A patent/NZ577390A/xx not_active IP Right Cessation
- 2007-11-02 EP EP07834664A patent/EP2086545A2/fr not_active Withdrawn
- 2007-11-02 AU AU2007314735A patent/AU2007314735B2/en not_active Ceased
- 2007-11-02 AU AU2007314734A patent/AU2007314734B2/en not_active Ceased
- 2007-11-02 CN CN201310556256.6A patent/CN103599536A/zh active Pending
- 2007-11-02 BR BRPI0718396-8A2A patent/BRPI0718396A2/pt not_active IP Right Cessation
- 2007-11-02 KR KR1020097011485A patent/KR20090115113A/ko not_active Application Discontinuation
- 2007-11-02 JP JP2009535226A patent/JP2010509211A/ja not_active Withdrawn
- 2007-11-02 JP JP2009535228A patent/JP2010509213A/ja active Pending
- 2007-11-02 CA CA2668316A patent/CA2668316C/fr not_active Expired - Fee Related
- 2007-11-02 CN CNA2007800462422A patent/CN101557812A/zh active Pending
- 2007-11-02 KR KR20157004613A patent/KR20150038251A/ko not_active Application Discontinuation
- 2007-11-02 CN CNA2007800491317A patent/CN101573119A/zh active Pending
- 2007-11-02 KR KR1020097011483A patent/KR101578224B1/ko active IP Right Grant
- 2007-11-02 BR BRPI0717963-4A2A patent/BRPI0717963A2/pt not_active IP Right Cessation
- 2007-11-02 KR KR1020097011486A patent/KR20090111803A/ko active Application Filing
- 2007-11-02 PT PT78346632T patent/PT2086544E/pt unknown
- 2007-11-02 ES ES07834663.2T patent/ES2561946T3/es active Active
- 2007-11-02 CN CN2007800474487A patent/CN101563086B/zh not_active Expired - Fee Related
- 2007-11-02 HU HUE07834663A patent/HUE026752T2/en unknown
- 2007-11-02 JP JP2009535227A patent/JP2010509212A/ja active Pending
- 2007-11-02 WO PCT/NL2007/050533 patent/WO2008054213A2/fr active Application Filing
- 2007-11-02 RU RU2009120988/15A patent/RU2464027C2/ru not_active IP Right Cessation
- 2007-11-02 RU RU2009120992/15A patent/RU2491073C2/ru not_active IP Right Cessation
- 2007-11-02 WO PCT/NL2007/050534 patent/WO2008054214A2/fr active Application Filing
- 2007-11-02 BR BRPI0717856-5A2A patent/BRPI0717856A2/pt active Search and Examination
- 2007-11-02 ZA ZA200903835A patent/ZA200903835B/xx unknown
- 2007-11-02 MX MX2009004695A patent/MX2009004695A/es not_active Application Discontinuation
- 2007-11-02 CA CA2668317A patent/CA2668317C/fr not_active Expired - Fee Related
- 2007-11-02 NZ NZ577393A patent/NZ577393A/xx not_active IP Right Cessation
- 2007-11-02 EP EP07834665A patent/EP2086548A2/fr not_active Withdrawn
- 2007-11-02 CN CN2013102891472A patent/CN103381270A/zh active Pending
- 2007-11-02 AU AU2007314736A patent/AU2007314736B2/en not_active Ceased
- 2007-11-02 US US12/513,358 patent/US8575139B2/en active Active
- 2007-11-02 RS RS20160069A patent/RS54541B1/en unknown
- 2007-11-02 US US12/513,357 patent/US8648060B2/en active Active
- 2007-11-02 UA UAA201214342A patent/UA115647C2/uk unknown
- 2007-11-02 EP EP15167346.4A patent/EP2937086A1/fr not_active Withdrawn
- 2007-11-02 EP EP07834663.2A patent/EP2086544B1/fr active Active
-
2009
- 2009-04-30 IL IL198461A patent/IL198461A/en active IP Right Grant
- 2009-04-30 IL IL198460A patent/IL198460A/en active IP Right Grant
- 2009-04-30 IL IL198459A patent/IL198459A/en active IP Right Grant
- 2009-06-03 NO NO20092143A patent/NO343597B1/no not_active IP Right Cessation
- 2009-06-03 NO NO20092146A patent/NO20092146L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092145A patent/NO20092145L/no not_active Application Discontinuation
-
2010
- 2010-04-07 HK HK10103442.6A patent/HK1135038A1/xx not_active IP Right Cessation
-
2012
- 2012-06-20 RU RU2012125827A patent/RU2646447C2/ru not_active IP Right Cessation
- 2012-07-10 US US13/545,916 patent/US8669242B2/en active Active
-
2013
- 2013-09-06 JP JP2013185156A patent/JP5748238B2/ja not_active Expired - Fee Related
- 2013-10-08 US US14/049,005 patent/US9211334B2/en not_active Expired - Fee Related
- 2013-10-16 JP JP2013215284A patent/JP2014055142A/ja active Pending
-
2014
- 2014-01-03 US US14/147,393 patent/US20140121189A1/en not_active Abandoned
- 2014-01-03 US US14/147,415 patent/US20140121190A1/en not_active Abandoned
- 2014-01-08 JP JP2014001289A patent/JP2014111608A/ja active Pending
- 2014-06-20 PH PH12014501440A patent/PH12014501440A1/en unknown
- 2014-08-12 PH PH12014501821A patent/PH12014501821A1/en unknown
-
2015
- 2015-03-16 IL IL237786A patent/IL237786A0/en unknown
- 2015-05-07 JP JP2015094573A patent/JP6357131B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,204 patent/US9597335B2/en not_active Expired - Fee Related
-
2016
- 2016-02-01 HR HRP20160108T patent/HRP20160108T1/hr unknown
- 2016-02-12 CY CY20161100116T patent/CY1117191T1/el unknown
- 2016-10-27 IL IL248563A patent/IL248563B/en active IP Right Grant
-
2017
- 2017-02-21 US US15/438,547 patent/US10314848B2/en not_active Expired - Fee Related
- 2017-05-10 JP JP2017093563A patent/JP2017132809A/ja active Pending
-
2019
- 2019-05-14 US US16/412,276 patent/US20190262359A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2668320A1 (fr) | Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel | |
| NO20090610L (no) | Faste preparater omfattende tadalafil og minst en baerer | |
| WO2006096439A3 (fr) | Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees | |
| WO2007146124A3 (fr) | Inhibiteurs de pde5 substitué | |
| WO2005107810A3 (fr) | Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme | |
| TW200716631A (en) | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| WO2006096434A3 (fr) | Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete | |
| WO2004074266A8 (fr) | 1,2,4-triazines inhibant le vih | |
| WO2007087452A3 (fr) | Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci | |
| WO2008039218A3 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| WO2006116148A3 (fr) | Traitement de l'abus de substances toxiques | |
| WO2005102392A3 (fr) | Methodes de traitement d'une infection a vih | |
| WO2004030611A3 (fr) | Inhibiteurs non nucleosidiques de transcriptases inverses | |
| WO2007026024A3 (fr) | Benzodiazepines en tant qu'inhibiteurs du vhc | |
| WO2007103200A3 (fr) | Formulation orale à libération contrôlée pour des agents sédatifs ou hypnotiques | |
| WO2008028965A3 (fr) | Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications | |
| WO2008116890A3 (fr) | Nouvelles compositions pharmaceutiques | |
| WO2008026156A3 (fr) | Compositions therapeutiques | |
| WO2008023362A3 (fr) | Traitement du cancer | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
| WO2005082413A3 (fr) | Combinaison de ciclesonide et de glycopyrronium | |
| WO2004071374A3 (fr) | Compositions pharmaceutiques d'administration orale une fois par jour | |
| RS51912B (en) | 1,2,3,4-TETRAHYDROPYROLO (1,2-a) PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYROLO (1,2-a) (1,4) -DIAZEPIN-7-CARBOXAMIDE DERIVATIVES THEIR OBTAINING AND THERAPEUTIC APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191104 |